Annual report pursuant to Section 13 and 15(d)

Accrued Liabilities and other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail)

v3.3.1.900
Accrued Liabilities and other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($)
$ in Thousands
Dec. 31, 2015
Dec. 31, 2014
Accrued expenses:    
Professional fees $ 382 $ 837
Salaries, bonuses and related benefits 2,492 598
Accrued severance 0 38
Ovamed manufacturing rights 1,500 1,000
Research and development 810 832
Dr. Falk Pharma milestone 2,717  
Lease impairment 146 165
Other 523 213
Total accrued expenses 8,570 3,683
Other long-term liabilities:    
Ovamed manufacturing rights - long-term component 0 334
Long-term lease abandonment charge 91 268
Deferred rent 493 120
Total other long-term liabilities $ 584 $ 722